Hostname: page-component-848d4c4894-8bljj Total loading time: 0 Render date: 2024-07-06T10:20:54.708Z Has data issue: false hasContentIssue false
  • English
  • Français

Method of Addition of Bromocriptine to the Drug Regime of Patients with Advanced Parkinson’s Disease

Published online by Cambridge University Press:  18 September 2015

J. David Grimes  and
Mohamed N. Hassan
J. David Grimes*
Affiliation:
the Parkinson’s Disease Clinic, Department of Neurology, Ottawa Civic Hospital and the University of Ottawa
Mohamed N. Hassan
Affiliation:
the Parkinson’s Disease Clinic, Department of Neurology, Ottawa Civic Hospital and the University of Ottawa
*
1081 Carling Avenue, Ottawa, Ontario, Canada KIY 4G2
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Using a method of a gradual increase of bromocriptine with a concomitant reduction of Sinemet® (levodopa 250 mg + carhidopa 25 mg), 19 patients with advanced Parkinson’s disease have been treated for periods of up to 22 months and 16 of them have shown improvements of varying degrees. Eighteen patients were able to tolerate bromocriptine addition, with early transient adverse effects occurring in seven cases. In contrast to several previously reported studies, it was found necessary to withdraw bromocriptine in only one case.

With the drugs currently available, bromocriptine has a role in the management of patients with advanced Parkinson’s disease. The method described here may allow a greater number of patients to be given a trial with this drug.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 8 , Issue 1 , February 1981 , pp. 31 - 34
Copyright
Copyright © Canadian Neurological Sciences Federation 1981

References

Calne, D.B., Williams, A.C., Neophytides, A., Plotkin, C., Nutt, J.G. and Teychenne, P.F. (1978). Long-term treatment of Parkinsonism with bromocriptine. Lancet, 1: 735–738.CrossRefGoogle ScholarPubMed
Fahn, S., Cote, L.J., Snider, S.R., Barrett, R.E. and Isgreen, W.P. (1979). The role of bromocriptine in the treatment of parkinsonism. Neurology, 29: 1077–1083.CrossRefGoogle ScholarPubMed
Lieberman, A.N., Kupersmith, M., Gopinathan, G., Estey, E., Goodgold, A. and Goldstein, M. (1979). Bromocriptine in Parkinson disease: Further studies. Neurology, 29: 363–369.CrossRefGoogle ScholarPubMed
Pearce, I. and Pearce, J.M.S. (1978). Bromocriptine in Parkinsonism. British Medical Journal, 1: 1402–1404.CrossRefGoogle ScholarPubMed
Rascol, A., Guiraud, B., Montastruc, J.L., David, J. and Clanet, M. (1979). Long-term treatment of Parkinson’s disease with bromocriptine. Journal of Neurology, Neurosurgery, and Psychiatry, 42: 143–150.Google Scholar
Teychenne, P.F., Leigh, P.N., Reid, J.L., Calne, D.B., Greenacre, J.K. and Petrie, A. (1975). Idiopathic Parkinsonism treated with bromocriptine. Lancet, 2: 473–476.CrossRefGoogle ScholarPubMed